Amgen, Inc. (NASDAQ:AMGN) Shares Sold by Opus Capital Group LLC

Opus Capital Group LLC decreased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 40.7% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,609 shares of the medical research company’s stock after selling 1,791 shares during the quarter. Opus Capital Group LLC’s holdings in Amgen were worth $496,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the business. BlackRock Inc. boosted its stake in shares of Amgen by 2.0% in the fourth quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock valued at $8,979,621,000 after buying an additional 906,568 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in shares of Amgen by 20,103.6% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock valued at $161,000 after buying an additional 31,268,677 shares in the last quarter. Northern Trust Corp boosted its position in Amgen by 4.7% during the fourth quarter. Northern Trust Corp now owns 9,182,050 shares of the medical research company’s stock worth $1,787,470,000 after purchasing an additional 408,675 shares in the last quarter. Geode Capital Management LLC boosted its position in Amgen by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after purchasing an additional 482,760 shares in the last quarter. Finally, Norges Bank purchased a new stake in Amgen during the fourth quarter worth $1,283,248,000. Institutional investors own 77.29% of the company’s stock.

A number of analysts have commented on the company. Zacks Investment Research downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. BidaskClub upgraded Amgen from a “sell” rating to a “hold” rating in a research report on Tuesday. Mizuho reiterated a “buy” rating and set a $208.00 target price on shares of Amgen in a research report on Friday, May 17th. Royal Bank of Canada reiterated a “neutral” rating and set a $192.00 target price on shares of Amgen in a research report on Tuesday, May 21st. Finally, Credit Suisse Group assumed coverage on Amgen in a research report on Monday, May 20th. They set an “outperform” rating and a $208.00 target price on the stock. Ten analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $208.35.

In related news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total value of $386,360.00. Following the completion of the transaction, the director now directly owns 15,092 shares in the company, valued at $2,915,472.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 6,000 shares of company stock valued at $1,089,180 over the last quarter. Insiders own 0.25% of the company’s stock.

Amgen stock opened at $175.60 on Thursday. The firm has a market capitalization of $106.51 billion, a P/E ratio of 12.19, a price-to-earnings-growth ratio of 2.13 and a beta of 1.14. Amgen, Inc. has a 52 week low of $166.30 and a 52 week high of $210.19. The company has a quick ratio of 2.53, a current ratio of 2.77 and a debt-to-equity ratio of 2.71.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.45 by $0.11. The firm had revenue of $5.56 billion during the quarter, compared to analyst estimates of $5.55 billion. Amgen had a return on equity of 71.02% and a net margin of 34.00%. The business’s quarterly revenue was up .1% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.47 earnings per share. Research analysts predict that Amgen, Inc. will post 13.91 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.com-unik.info/2019/06/13/amgen-inc-nasdaqamgn-shares-sold-by-opus-capital-group-llc.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

See Also: Key terms to understand channel trading

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit